These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 37047023)

  • 1. Peripheral Biomarkers in Manifest and Premanifest Huntington's Disease.
    Morena E; Romano C; Marconi M; Diamant S; Buscarinu MC; Bellucci G; Romano S; Scarabino D; Salvetti M; Ristori G
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Huntingtin silencing delays onset and slows progression of Huntington's disease: a biomarker study.
    Liu H; Zhang C; Xu J; Jin J; Cheng L; Miao X; Wu Q; Wei Z; Liu P; Lu H; van Zijl PCM; Ross CA; Hua J; Duan W
    Brain; 2021 Nov; 144(10):3101-3113. PubMed ID: 34043007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease.
    Byrne LM; Rodrigues FB; Johnson EB; Wijeratne PA; De Vita E; Alexander DC; Palermo G; Czech C; Schobel S; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
    Sci Transl Med; 2018 Sep; 10(458):. PubMed ID: 30209243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary Huntingtin protein is uniquely associated with clinical features of Huntington's disease.
    Parkin GM; Corey-Bloom J; Snell C; Smith H; Laurenza A; Daldin M; Bresciani A; Thomas EA
    Sci Rep; 2023 Jan; 13(1):1034. PubMed ID: 36658243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
    Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
    Elife; 2021 Apr; 10():. PubMed ID: 33871358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting.
    Nielsen SM; Vinther-Jensen T; Nielsen JE; Nørremølle A; Hasholt L; Hjermind LE; Josefsen K
    J Neurol Sci; 2016 Mar; 362():326-32. PubMed ID: 26944172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elevated plasma and CSF neurofilament light chain concentrations are stabilized in response to mutant huntingtin lowering in the brains of Huntington's disease mice.
    Caron NS; Byrne LM; Lemarié FL; Bone JN; Aly AE; Ko S; Anderson C; Casal LL; Hill AM; Hawellek DJ; McColgan P; Wild EJ; Leavitt BR; Hayden MR
    Transl Neurodegener; 2024 Oct; 13(1):50. PubMed ID: 39380076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis.
    Byrne LM; Rodrigues FB; Blennow K; Durr A; Leavitt BR; Roos RAC; Scahill RI; Tabrizi SJ; Zetterberg H; Langbehn D; Wild EJ
    Lancet Neurol; 2017 Aug; 16(8):601-609. PubMed ID: 28601473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease.
    Rodrigues FB; Byrne LM; Tortelli R; Johnson EB; Wijeratne PA; Arridge M; De Vita E; Ghazaleh N; Houghton R; Furby H; Alexander DC; Tabrizi SJ; Schobel S; Scahill RI; Heslegrave A; Zetterberg H; Wild EJ
    Sci Transl Med; 2020 Dec; 12(574):. PubMed ID: 33328328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.
    Wild EJ; Boggio R; Langbehn D; Robertson N; Haider S; Miller JR; Zetterberg H; Leavitt BR; Kuhn R; Tabrizi SJ; Macdonald D; Weiss A
    J Clin Invest; 2015 May; 125(5):1979-86. PubMed ID: 25844897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Huntington's Disease: Relationship Between Phenotype and Genotype.
    Sun YM; Zhang YB; Wu ZY
    Mol Neurobiol; 2017 Jan; 54(1):342-348. PubMed ID: 26742514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A clinical classification acknowledging neuropsychiatric and cognitive impairment in Huntington's disease.
    Vinther-Jensen T; Larsen IU; Hjermind LE; Budtz-Jørgensen E; Nielsen TT; Nørremølle A; Nielsen JE; Vogel A
    Orphanet J Rare Dis; 2014 Jul; 9():114. PubMed ID: 25026978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. What, When and How to Measure-Peripheral Biomarkers in Therapy of Huntington's Disease.
    Przybyl L; Wozna-Wysocka M; Kozlowska E; Fiszer A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of GSK-3 ameliorates the pathogenesis of Huntington's disease.
    Rippin I; Bonder K; Joseph S; Sarsor A; Vaks L; Eldar-Finkelman H
    Neurobiol Dis; 2021 Jul; 154():105336. PubMed ID: 33753290
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression.
    Weiss A; Träger U; Wild EJ; Grueninger S; Farmer R; Landles C; Scahill RI; Lahiri N; Haider S; Macdonald D; Frost C; Bates GP; Bilbe G; Kuhn R; Andre R; Tabrizi SJ
    J Clin Invest; 2012 Oct; 122(10):3731-6. PubMed ID: 22996692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR-Cas9 Mediated Gene-Silencing of the Mutant Huntingtin Gene in an In Vitro Model of Huntington's Disease.
    Kolli N; Lu M; Maiti P; Rossignol J; Dunbar GL
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28368337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retinal thickness as a biomarker of cognitive impairment in manifest Huntington's disease.
    Murueta-Goyena A; Del Pino R; Acera M; Teijeira-Portas S; Romero D; Ayala U; Fernández-Valle T; Tijero B; Gabilondo I; Gómez Esteban JC
    J Neurol; 2023 Aug; 270(8):3821-3829. PubMed ID: 37079031
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive Control, Learning, and Clinical Motor Ratings Are Most Highly Associated with Basal Ganglia Brain Volumes in the Premanifest Huntington's Disease Phenotype.
    Misiura MB; Lourens S; Calhoun VD; Long J; Bockholt J; Johnson H; Zhang Y; Paulsen JS; Turner JA; Liu J; Kara B; Fall E;
    J Int Neuropsychol Soc; 2017 Feb; 23(2):159-170. PubMed ID: 28205498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a ligand for in vivo imaging of mutant huntingtin in Huntington's disease.
    Bertoglio D; Bard J; Hessmann M; Liu L; Gärtner A; De Lombaerde S; Huscher B; Zajicek F; Miranda A; Peters F; Herrmann F; Schaertl S; Vasilkovska T; Brown CJ; Johnson PD; Prime ME; Mills MR; Van der Linden A; Mrzljak L; Khetarpal V; Wang Y; Marchionini DM; Skinbjerg M; Verhaeghe J; Dominguez C; Staelens S; Munoz-Sanjuan I
    Sci Transl Med; 2022 Feb; 14(630):eabm3682. PubMed ID: 35108063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.
    Suelves N; Kirkham-McCarthy L; Lahue RS; Ginés S
    Sci Rep; 2017 Jul; 7(1):6082. PubMed ID: 28729730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.